1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Emma
Walmsley
|
|||
b)
|
Position/status
|
Chief
Executive Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
29
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Diana
Conrad
|
|||
b)
|
Position/status
|
Chief
People Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
5
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James
Ford
|
|||
b)
|
Position/status
|
SVP
and Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
11
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally
Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
19
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Luke
Miels
|
|||
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
3
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
David
Redfern
|
|||
b)
|
Position/status
|
President
Corporate Development
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
76
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Regis
Simard
|
|||
b)
|
Position/status
|
President,
Global Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
29
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Philip
Thomson
|
|||
b)
|
Position/status
|
President,
Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
48
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Deborah
Waterhouse
|
|||
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
62
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria
Whyte
|
|||
b)
|
Position/status
|
SVP
& Company Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on shares held through the Company's
Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.3921
|
58
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally
Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria
Whyte
|
|||
b)
|
Position/status
|
SVP
& Company Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
123
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Iain
Whyte
|
|||
b)
|
Position/status
|
PCA
of Ms V Whyte (SVP & Company Secretary)
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1,152
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Emma
Walmsley
|
|||
b)
|
Position/status
|
Chief
Executive Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
105.836
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Diana
Conrad
|
|||
b)
|
Position/status
|
Chief
People Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1,233.149
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James
Ford
|
|||
b)
|
Position/status
|
SVP
and Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1,024.598
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally
Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
453.008
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dylan
Jackson
|
|||
b)
|
Position/status
|
PCA
of Sally Jackson (SVP, Global Communications and CEO
Office)
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
140.210
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
David
Redfern
|
|||
b)
|
Position/status
|
President
Corporate Development
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
6,278.135
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Regis
Simard
|
|||
b)
|
Position/status
|
President, Global
Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
2,616.351
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Philip
Thomson
|
|||
b)
|
Position/status
|
President,
Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
2,144.723
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Kate
Thomson
|
|||
b)
|
Position/status
|
PCA
of Philip Thomson (President, Global Affairs)
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
109.382
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Deborah
Waterhouse
|
|||
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1,279.528
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Tony
Wood
|
|||
b)
|
Position/status
|
Chief
Scientific Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1,270.306
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria
Whyte
|
|||
b)
|
Position/status
|
SVP
& Company Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.4016
|
1.332
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-09
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Elizabeth
McKee Anderson
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
26
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Charles
Bancroft
|
|||
b)
|
Position/status
|
Senior
Independent Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
340
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr
Hal Barron
|
|||
b)
|
Position/status
|
Non-Executive
Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
28
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr
Anne Beal
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
34
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr
Harry Dietz
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
32
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr
Jeannie Lee
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
13
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr
Vishal Sikka
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 9 October 2025
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.7375
|
99
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2025-10-10
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: October
13, 2025
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|